JP2009527559A - 二官能性レソルシノール、チオレソルシノールおよびジチオレソルシノール誘導体金属キレート形成性結合体 - Google Patents

二官能性レソルシノール、チオレソルシノールおよびジチオレソルシノール誘導体金属キレート形成性結合体 Download PDF

Info

Publication number
JP2009527559A
JP2009527559A JP2008556387A JP2008556387A JP2009527559A JP 2009527559 A JP2009527559 A JP 2009527559A JP 2008556387 A JP2008556387 A JP 2008556387A JP 2008556387 A JP2008556387 A JP 2008556387A JP 2009527559 A JP2009527559 A JP 2009527559A
Authority
JP
Japan
Prior art keywords
alkyl
hydroxyl
nitro
cyano
phosphato
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2008556387A
Other languages
English (en)
Japanese (ja)
Inventor
デニス エー． ムーア，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mallinckrodt Inc
Original Assignee
Mallinckrodt Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mallinckrodt Inc filed Critical Mallinckrodt Inc
Publication of JP2009527559A publication Critical patent/JP2009527559A/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
    • A61K47/551—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds one of the codrug's components being a vitamin, e.g. niacinamide, vitamin B3, cobalamin, vitamin B12, folate, vitamin A or retinoic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0002—General or multifunctional contrast agents, e.g. chelated agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/085—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier conjugated systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/14—Peptides, e.g. proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
JP2008556387A 2006-02-24 2007-02-20 二官能性レソルシノール、チオレソルシノールおよびジチオレソルシノール誘導体金属キレート形成性結合体 Pending JP2009527559A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US77678506P 2006-02-24 2006-02-24
US78436306P 2006-03-21 2006-03-21
PCT/US2007/004427 WO2007100563A2 (en) 2006-02-24 2007-02-20 Bifunctional resorcinol, thioresorcinol, and dithioresorcinol derivative metal chelating conjugates

Publications (1)

Publication Number Publication Date
JP2009527559A true JP2009527559A (ja) 2009-07-30

Family

ID=38308626

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008556387A Pending JP2009527559A (ja) 2006-02-24 2007-02-20 二官能性レソルシノール、チオレソルシノールおよびジチオレソルシノール誘導体金属キレート形成性結合体

Country Status (7)

Country Link
US (1) US8119103B2 (US20090082324A1-20090326-C00003.png)
EP (1) EP1988925A2 (US20090082324A1-20090326-C00003.png)
JP (1) JP2009527559A (US20090082324A1-20090326-C00003.png)
KR (1) KR20080099279A (US20090082324A1-20090326-C00003.png)
CA (1) CA2643145C (US20090082324A1-20090326-C00003.png)
IL (1) IL193518A0 (US20090082324A1-20090326-C00003.png)
WO (1) WO2007100563A2 (US20090082324A1-20090326-C00003.png)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009530294A (ja) * 2006-03-15 2009-08-27 マリンクロット インコーポレイテッド 置換芳香族部分を有するキレート化接合体およびその誘導体

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100055043A1 (en) * 2006-10-30 2010-03-04 Moore Dennis A Poly-Halo Metal X-ray Contrast Agents
US9005577B2 (en) * 2008-04-30 2015-04-14 Siemens Medical Solutions Usa, Inc. Substrate based PET imaging agents
EP3101012A1 (en) 2015-06-04 2016-12-07 Bayer Pharma Aktiengesellschaft New gadolinium chelate compounds for use in magnetic resonance imaging
EP3544964B1 (en) 2016-11-28 2020-06-17 Bayer Pharma Aktiengesellschaft High relaxivity gadolinium chelate compounds for use in magnetic resonance imaging
SI3568205T1 (sl) 2017-01-12 2023-12-29 Radiomedix Inc. Zdravljenje rakastih celic, ki prekomerno izražajo receptorje za somatostatin, z uporabo derivatov okreotida, kelatiranih v radioizotope
AU2019382881A1 (en) 2018-11-23 2021-05-20 Bayer Aktiengesellschaft Formulation of contrast media and process of preparation thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6602989B1 (en) * 2000-05-17 2003-08-05 The Research Foundation Of State University Of New York Synthesis, characterization, and application of pyridylazo bioconjugates as diagnostic and therapeutic agents

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI48507C (fi) 1972-06-29 1974-10-10 Orion Yhtymae Oy Menetelmä metallispesifisten atsoväriaineiden kiinnittämiseksi silloit tajaryhmän avulla kiinteään kantaja-ainekseen, erikoisesti selluloosak uituun.
JPS6048916A (ja) 1983-08-29 1985-03-16 Risuburan Prod:Kk 白髪を黒くする整髪用乳化物の製造方法
MX174467B (es) * 1986-01-23 1994-05-17 Squibb & Sons Inc 1,4,7-triscarboximetil-1,4,7,10-tetraazaciclodo decano substituido en 1 y compuestos analogos
CN1016693B (zh) * 1987-06-05 1992-05-20 北京工业大学 新顺铂铬合物的制备方法
EP0420942A1 (en) * 1988-06-24 1991-04-10 The Dow Chemical Company Macrocyclic bifunctional chelants, complexes thereof and their antibody conjugates
US5559149A (en) * 1990-01-29 1996-09-24 Johnson & Johnson Consumer Products, Inc. Skin care compositions containing retinoids
US5186923A (en) * 1990-10-10 1993-02-16 Brigham And Womens Hospital Enhancement of cellular accumulation of lipophilic cationic organometallic compounds by reduction of intramembrane potential
US5147632A (en) * 1990-10-31 1992-09-15 Warner-Lambert Company Anti-plaque compositions comprising a combination of morpholinoamino alcohol and chelating agent
US5310539A (en) * 1991-04-15 1994-05-10 Board Of Regents, The University Of Texas System Melanin-based agents for image enhancement
MX9305039A (es) * 1992-08-19 1994-05-31 Mallinckrodt Medical Inc Ligandos para ga-68 para aplicaciones cardiacas de tep.
JPH1053515A (ja) 1996-08-09 1998-02-24 Ajinomoto Co Inc 皮膚外用剤
JPH10130155A (ja) 1996-10-28 1998-05-19 Chiyuuyakuken:Kk 病変組織治療用組成物、その製法およびその用途
EP0976392A1 (en) 1998-07-29 2000-02-02 Unilever Plc Liquid compositions comprising antioxidants and ED3A-derived chelating surfactants as stabilizers
US6685914B1 (en) * 1999-09-13 2004-02-03 Bristol-Myers Squibb Pharma Company Macrocyclic chelants for metallopharmaceuticals
PE20011099A1 (es) 2000-02-14 2001-11-23 Procter & Gamble Composiciones para el suministro topico de un agente farmaceuticamente activo que tiene oxidacion reducida
US20030161862A1 (en) * 2000-03-28 2003-08-28 Susumu Hizukuri Bacterial growth regulators or inhibitors with the use of 1,5-d-anhydrofructose
US6710192B2 (en) * 2001-10-16 2004-03-23 Arco Chemical Technology, L.P. Dense phase epoxidation
WO2003045449A1 (fr) * 2001-11-26 2003-06-05 Yugen Kaisha Okada Giken Agent desodorisant et preparation de shampooing cosmetique le contenant
US7176239B2 (en) * 2003-07-11 2007-02-13 Suming Wang Methods and compositions for treatment of Ataxia-telangeictasia
CA2631784A1 (en) 2005-11-29 2007-06-07 Mallinckrodt Inc. Bifunctional metal chelating conjugates

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6602989B1 (en) * 2000-05-17 2003-08-05 The Research Foundation Of State University Of New York Synthesis, characterization, and application of pyridylazo bioconjugates as diagnostic and therapeutic agents

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
JPN5009000969; ＢＥＲＧＥＲＯＮ　Ｒ　Ｊ: ＪＯＵＲＮＡＬ　ＯＦ　ＭＥＤＩＣＩＮＡＬ　ＣＨＥＭＩＳＴＲＹ Ｖ４６　Ｎ１, 20030102, Ｐ１６-２４, ＡＭＥＲＩＣＡＮ　ＣＨＥＭＩＣＡＬ　ＳＯＣＩＥＴＹ． *
JPN5009000970; ＳＵＧＩＩ，ＡＴＳＵＳＨＩ: ＴＡＬＡＮＴＡ Ｖ２６　Ｎ１０, 1979, Ｐ９７０-９７２ *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009530294A (ja) * 2006-03-15 2009-08-27 マリンクロット インコーポレイテッド 置換芳香族部分を有するキレート化接合体およびその誘導体

Also Published As

Publication number Publication date
US8119103B2 (en) 2012-02-21
IL193518A0 (en) 2011-08-01
WO2007100563A2 (en) 2007-09-07
US20090082324A1 (en) 2009-03-26
EP1988925A2 (en) 2008-11-12
WO2007100563A3 (en) 2008-03-20
CA2643145A1 (en) 2007-09-07
CA2643145C (en) 2014-04-29
KR20080099279A (ko) 2008-11-12

Similar Documents

Publication Publication Date Title
US20090053137A1 (en) Chelating Conjugates Having a Substituted Aromatic Moiety and Derivatives Thereof
TWI657827B (zh) 用於正子斷層掃描之化合物
KR102276804B1 (ko) 방사성 약물 컨쥬게이트
EP2341944B1 (en) Conjugates of hexose and metal coordinating compounds for imaging purposes
US20100111858A1 (en) Diangostic and Therapeutic Cyclooxygenase-2 Binding Ligands
US8119103B2 (en) Bifunctional resorcinol, thioresorcinol, and dithioresorcinol derivative metal chelating conjugates
BR112021005931A2 (pt) composto, complexo e composição farmacêutica
JP5099919B2 (ja) 二官能性金属キレートコンジュゲート
EP2476683A2 (en) Novel tetra-aza macrocyclic compound, method for preparing same, and use thereof
WO2015119763A1 (en) Al-f-18-labeled, al-f-19-labeled and ga-68-labeled gastrin-releasing peptide receptor (grpr)-antagonists for imaging of prostate cancer
CN101316615A (zh) 双官能金属螯合共轭物
KR101336073B1 (ko) 암 진단용 ｓｐｅｃｔ／ｍｒｉ 이중 조영제 조성물 및 이를 이용한 ｓｐｅｃｔ／ｍｒｉ이중영상을 획득하는 방법
US20100055043A1 (en) Poly-Halo Metal X-ray Contrast Agents
CN101389355A (zh) 双功能间苯二酚、硫代间苯二酚和二硫代间苯二酚衍生物金属螯合共轭物
CN117642184A (zh) 具有刷状缘膜酶可裂解接头的叶酸受体靶向缀合物以及在癌症成像和治疗中的使用方法

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20100121

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110114

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120723

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120921

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20130205